A5077955682- Lipoproteins and Cardiovascular Health
- Pharmaceutical Economics and Policy
- Cancer, Lipids, and Metabolism
- Computational Drug Discovery Methods
- Clostridium difficile and Clostridium perfringens research
- Microscopic Colitis
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Helicobacter pylori-related gastroenterology studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Hormonal Regulation and Hypertension
- Cancer Immunotherapy and Biomarkers
- Viral Infections and Outbreaks Research
- Health Systems, Economic Evaluations, Quality of Life
- Blood Pressure and Hypertension Studies
- Pharmacology and Obesity Treatment
- Viral Infections and Vectors
- Cancer Research and Treatments
- Pharmaceutical Practices and Patient Outcomes
- Lung Cancer Research Studies
- Diabetes Treatment and Management
- Acute Myocardial Infarction Research
- Colorectal Cancer Treatments and Studies
- Heart Failure Treatment and Management
- Chronic Lymphocytic Leukemia Research
- Atrial Fibrillation Management and Outcomes
Merck & Co., Inc., Rahway, NJ, USA (United States)
2012-2022
University of North Carolina at Chapel Hill
2017
Global Vaccines (United States)
2017
Sterling Research Group
2011
Iowa City Public Library
2010
University of Richmond
2009
Charing Cross Hospital
1989
Royal London Hospital
1984
Bezlotoxumab is a human monoclonal antibody against Clostridium difficile toxin B indicated to prevent C. infection (CDI) recurrence (rCDI) in adults at high risk for rCDI. This post hoc analysis of pooled monocolonal antibodies C.difficile therapy (MODIFY) I/II data assessed bezlotoxumab efficacy participants with characteristics associated increased The population was the modified intent-to-treat who received or placebo (n = 1554) by factors rCDI that were prespecified statistical plan:...
Background: Data on the average US costs of an outpatient visit, emergency room (ER) visit or hospitalization for migraine are scant, with most recent available values based healthcare charges reported from 1994 data. Methods: We estimated associated and ER visits inpatient hospitalizations related to retrospectively obtained 2007 Medstat MarketScan Commercial Claims & Encounters database. Tabulated reflected payments insurers, patients other sources. All were adjusted 2010 dollars....
8020 Background: This Phase I study evaluated the safety, tolerability, and clinical activity of MK-3475, a selective anti-PD-1 antibody that blocks interaction between programmed death-1 (PD-1) on T-cells PD-L1 PD-L2 tumor cells in pts with previously-treated, progressive locally advanced or metastatic NSCLC. Methods: Previously-treated NSCLC whose tumors expressed any detectable using preliminary immunohistochemical assay were randomized to MK-3475 at 10 mg/kg every 2 weeks (Q2W) 3 (Q3W)....
8007 Background: Programmed death-1 (PD-1) receptor-ligand interaction inhibits T cell activation against tumor cells. MK-3475 is a potent and highly selective humanized monoclonal antibody PD-1 designed to directly block its with ligands, PD-L1 PD-L2, thus removing the inhibition of cancer. led prolonged anti-tumor activity in previously treated NSCLC patients. This Phase I study evaluated safety, tolerability, clinical as initial therapy patients locally advanced or metastatic NSCLC....
Background Although the rate of in‐hospital ischemic events after myocardial infarction ( MI ) has dramatically decreased, long‐term residual risk may remain substantial. However, most information on current is derived from highly selected randomized trials. Hypothesis In patients with previous and no prior stroke/transient attack (TIA), increases over time. Methods Using international Reduction Atherothrombosis for Continued Health REACH registry, we analyzed baseline characteristics 4‐year...
Despite current polysaccharide and conjugate vaccine use, pneumococcal diseases remain prevalent in older adults. VAX-24 is a 24-valent (PCV) containing eCRM, proprietary carrier protein with non-native amino acids (para-azidomethyl-L-phenylalanine) that undergo site-specific conjugation to polysaccharides have been activated small-molecule linker (dibenzocyclooctyne). Site-specific utilizing click chemistry enables consistent exposure of T-cell epitopes, reduction ratio, enhances...
Establishment of immune correlates protection can provide a measurable criterion for assessing against infection or disease. For some vaccines, such as the measles vaccine, antibodies serve correlate protection, but others, human papillomavirus, remains unknown. Merck & Co, Kenilworth, NJ, USA, in collaboration with multiple partners, developed live recombinant vesicular stomatitis virus vaccine (rVSVΔG-ZEBOV-GP [ERVEBO]) containing Zaire ebolavirus glycoprotein (GP) place GP to prevent...
Background Patients with symptomatic peripheral artery disease ( PAD ) are at high risk of ischemic events. However, data about predictors this limited. Hypothesis We analyzed baseline characteristics and 4‐year follow‐up patients enrolled in the international REduction Atherothrombosis for Continued Health REACH Registry no history stroke/transient attack to describe annual rates recurrent events globally geographically. Methods The primary outcome was systemic (composite cardiovascular...
Journal Article An assessment of the relationship between vasoconstrictor assay findings, clinical efficacy and skin thinning effects a variety undiluted diluted corticosteroid preparations Get access J. R. GIBSON, GIBSON Skin Department, The London Hospital, Whitechapel, EI IBB Dr John Gibson, IBB, U. K. Search for other works by this author on: Oxford Academic Google Scholar M. KIRSCH, KIRSCH Department Pharmacy, Chelsea College, C. DARLEY, DARLEY S. G. HARVEY, HARVEY A. BURKE, BURKE...
Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) are both associated with increased risk for atherosclerotic coronary heart disease (CHD). Thus, it is useful to know the relative efficacy of lipid-altering drugs in these patient populations.A double-blind, parallel group trial adult patients hypercholesterolaemia at high-CHD receiving atorvastatin 40 mg/day compared mg plus ezetimibe 10 (ezetimibe) vs. doubling 80 mg. This post hoc analysis reports lipid results grouped by...
Few clinical studies have focused on the efficacy of lipid-lowering therapies in patients ≥65 years. After stabilization atorvastatin 10 mg, hypercholesterolemic subjects years at high/very high risk for CHD and not LDL-C <1.81 mmol/L (with atherosclerotic vascular disease [AVD]) or <2.59 (without AVD) were randomized to ezetimibe mg plus uptitration 20 (6 weeks) followed by 40 (additional 6 weeks). A post-hoc analysis compared between-group differences percent attainment individual combined...
Despite documented benefits of lipid-lowering treatment in women, a considerable number are undertreated, and fewer achieve targets vs. men. Data were combined from 27 double-blind, active or placebo-controlled studies that randomized adult hypercholesterolemic patients to statin statin+ezetimibe. Consistency effect among men (n = 11,295) women 10,499) was assessed percent calculated evaluate the between-treatment ability specified levels between sexes. Baseline lipids hs-CRP generally...
The low-density lipoprotein cholesterol (LDL-C) lowering efficacy of switching to ezetimibe/simvastatin (EZ/S) 10/20 mg versus doubling the run-in statin dose (to simvastatin 40 or atorvastatin 20 mg) rosuvastatin 10 in subjects with cardiovascular disease (CVD) and diabetes was assessed. Endpoints included percentage change LDL-C patients achieving <70 mg/dL. Significantly greater reductions occurred when EZ/S overall population treated (all p < 0.001). reduction numerically ( =...
Some patients administered cholesterol-lowering therapies may experience an increase in the proportion of small LDL particles, which be misinterpreted as a worsening atherosclerotic coronary heart disease risk. This study assessed lipid effects adding ezetimibe to atorvastatin or doubling dose on low-density lipoprotein cholesterol (LDL-C) levels (and content subclasses), particle number (approximated by apolipoprotein B), and size. was multicenter, double-blind, randomized, parallel-group...
We estimated 30-day all-cause and Clostridium difficile infection (CDI)–associated hospital readmissions in participants at high risk of recurrent CDI enrolled MODIFY I/II. Bezlotoxumab-treated inpatients experienced fewer CDI-associated compared with placebo-treated inpatients, notably aged ≥65 years severe CDI. Clinical Trials Registration. NCT01241552 (MODIFY I) NCT01513239 II).
Aims: The aim of this analysis was to assess the overall safety and tolerability profiles various statins + ezetimibe vs. statin monotherapy explore in sub-populations grouped by age, race, sex. Methods: Study-level data were combined from 27 double-blind, placebo-controlled or active-comparator trials that randomized adult hypercholesterolemic patients for 6-24 weeks. In full cohort, % with AEs within treatment groups (statin: N = 10,517; ezetimibe: 11,714) assessed logistic regression...